Florian Buschek retweeted
If this post gets over 200k reactions, we’ll formally change our policy so that in reports, when someone “ran”, it will say “they skedaddled.”
Florian Buschek retweeted
It’s the 8 year anniversary of the podcast today. Below, the first 3 episodes of the pod, dropped on 11/18/18.
Just a little bit has happened in the world and markets over these last 8 years!
The VIX would make an all-time high of 83 and the 10-year an all-time low yield of 51 bps in 2020. The epic tightening cycle in 2022. The Tariff Tantrum in 2025. The oil shock and Iran war of 2026. This thing called AI is also worth a mention.
And US government debt outstanding has basically doubled from 21.8 to 40.7T.
277 episodes and a real privilege to host these discussions with some great thinkers on markets, the economy, and policy.
More to come! Thanks for listening.
Florian Buschek retweeted
Most interesting thing I read this week is about phone software for small businesses.
$CXDO pitched by @sammccolgan
Crexendo. Around 250 local telecom and IT providers rent its platform and sell phone service under their own brand, "much as an online shop runs on Shopify without its customers knowing". Over 8 million people make work calls on it, most never heard the name.
Stock has halved since June and closed Friday at $4.92. Every bear Sam talks to says the same thing, software growth is slowing. And licence sales did fall 25% in the first 9 months. Licences are the lumpy part though, capacity bought upfront in blocks, and new customers now start with smaller orders and top up as they move users across. The recurring line underneath grows 16 to 20% a year. Hold licences flat and software growth is back to about 13% in 2027 by Sam's maths.
For proof Sam went to BroadSoft, the incumbent in this exact market until Cisco bought it in 2018, which reported the same 2 lines for a decade. Its licence growth swung from -5% to +70%, back to roughly zero, up to 24%, down to -3%. Recurring line grew every quarter.
"The market is busy counting Crexendo's licence sales. I think it is missing the gorilla."
THE GORILLA
Management dropped pieces of it on calls and at conferences: what the AI receptionist earns per account, how many licensees resell it, a price range for call analysis, how fast the app store grows. "I have yet to see anyone put the pieces together." Sam did, and counts 5 income streams.
The number that matters. Crexendo makes about $80 a year from each business on a licensee's platform, and there are about 390,000 of them. CAIRO, the AI receptionist, earns it about $900 a year from each business that takes it.
THE NUMBERS
→ EBITDA (roughly cash profit before interest and tax) about $15M this year
→ Sam's base case: about $54M in 2028, about $40M if AI take-up is half the assumption
→ Analysts: $21M
→ Enterprise value about $150M at the $5.07 it was written at, so the price pays for almost none of it
THE DEALS
Spare cash goes into buying its own licensees at about 1.3x revenue. Same platform, so no migration risk. ESI cost about 10x EBITDA, about 8.4x after savings, and about 5.5x once Crexendo sells the AI add-ons to the customers it bought.
A year from now Sam values it at about $6.40 with no AI and no deals, $8.10 with the deals, $18 to $24 with the AI streams. First real test is year-end results, when management gives CAIRO numbers for the first time.
Sam and the fund are long.
"If I'm wrong, I own a growing, cash-generative business near its historical lows. If I'm even half right on AI, the shares are worth several times today's price."
Florian Buschek retweeted
Wentworth buys $51K of $DAIO.
DATA I/O CORP DAIO · William Wentworth, President · bought $51K · +37% stake · instruments for meas · filed 14:15 ET
My outlook on $ABVX - What is there to say that hasn't been said? Whatever, here I go anyway...
In the $83s right now I think it has to be one of the worst mispricings (and thus, hopefully, best opportunities) I have ever seen in biotech. Honestly, given the post P3 status of this asset...I would probably be pretty comfortable calling it "the" worst mispricing I've seen.
The stock's performance this year has *easily* been the most frustrating disappointment I've experienced in >10 years of doing this. The stock is down almost 40% YTD, and its underperformance versus the $XBI this year is nearly -70%.
What makes this price action so particularly infuriating is how incredibly positive their updates throughout the year have been.
I would've guessed that $ABVX languishing in the $80s would have been the result of a mixed UC maintenance readout, perhaps with a CR delta around 20% or below...The reality was *twice* that (~40%) - tying the best clinical remission data *ever* shown (by multi-black box warning drug Rinvoq). And on top of that we got an even bigger blue sky surprise with truly unheard of, unprecedented endoscopic remission rates...
...Then, on top of that, a few months later an unrelated trial reads out at UEGW that once and for all confirms that the endpoint GI docs should be treating to is...Endoscopic remission! The exact endpoint where the runner up to $ABVX isn't even visible in the rear view mirror...On their recent call, $ABVX management called this a "perfect storm". I agree. Not only did they present ER data so positive that nobody had even *modelled* for it as a *possibility*, but then just a few months later, that very endpoint becomes *THE* key endpoint for the disease...incredible!
Florian Buschek retweeted
Key date for market participates.
Everyone knows the market bottoms on GTA6 release date.
Florian Buschek retweeted
Anthropic published its IPO roadshow slides and presentation today.
Below, I provide some highlights.
Scroll through, and I've provided a link to all the slides at the end. 👇
1. $ANT is growing rapidly without burning cash and already has a fortress balance sheet.
Florian Buschek retweeted
What supposed to be the strongest earnings update, turned out to be disappointing throughout all RIN producers.
The overarching theme: none of them were able to actually capture strong spot-margins. For some it was stated as one-time operational issue ($DAR), others have to prove the market they are capable of achieving it.
As for $FF, I will keep it brief here since I covered it in detail in the subscriber discord.
First: management has done a poor job of communicating what has happened/ what drives economics here. I also think FF is a weird company, that no one really understands. No real analyst coverage and the chemical guys don’t get biodiesel and the RIN guys prefer $DAR or $CLMT.
The key to understand is that they have one big plant from where they operate both segments. Overhead is shared and allocation to COGS depends on utilization. Hence, if one segment operates at lower utilization, like the chemical segment did this quarter, it drags down the other segments GM.
This is one explanation, why margin looked extremely weak on surface. It doesn’t explain the entire gap to spot-margin but add to that some timing lag, and you can get a sense that actual realized margin on each gallon was not as bad as the market thinks after this sell-off.
Ultimately, we will know from Q4 onwards how close they can get to spot-margins.
Florian Buschek retweeted
New post with some weekend Thoughts: Datacenters, AI Stocks and the AI Religion
basehitinvesting.substack.co…
Florian Buschek retweeted
A friendly reminder that @KeithMcCullough's "Family Office" has returned by ~4% a year annualized.
(Analysis based upon stitching together ~10 self-published screen shots of his account over time: teapawt.org/choffstein/status/1843…)
Replying to @KeithMcCullough
Maybe, but I'd be less inclined to put it here.
"Among tactical allocation and multi-asset dynamic funds (around 400+ funds in Morningstar/Lipper categories), HECA ranks near the very bottom (410 out of ~415 peers)."
Florian Buschek retweeted
Much respect to this guy. Not only has he covered the name, along the RIN thesis, better than any other for years, all publicly, but also has no ego to point out what went worse than expected.
$CLMT no doubt had a great quarter. EBITDA came in 10% above the highest street estimate. But it did come in ~$50-100M less than my expectation primarily on MRL RD index capture (-$40M) & spot base oil cracks vs. contracts. I have to revise my peak cycle numbers down. I also think the mkt is now pricing in peak earnings rolling over imminently which means lower stock from multiple compression, which could prove to be very wrong in the near term.
Florian Buschek retweeted
$USIO reports its Q3 results on Tuesday after the market closes. Once again, a great setup for a beat and raise.
We are now used to 3 out of 4 biz lines growing at 20%+ rates, with the exception of card issuing. The latter has now implemented 4 school voucher programs that should contribute beautifully. Record ACH metrics have already been pre-announced. Re PayFac, mgmt “anticipate[s] a nice pickup in the third quarter from a couple of new ISVs that are ramping up.” And for Output Solutions, “inbound traffic is on the rise” and the “majority of that's reoccurring.”
Mgmt hinted at operating leverage during the LD Micro and Planet MicroCap conferences and also at a potential revenue raise from the current +14-16%: “As you can see, first half was at 17%, so we remain conservative in our guidance, and we’ll continue to evaluate that as the remainder of the year progresses.”
Added during the recent weakness and my pos is now as large as it can get. Rare setup and max conviction, but obv many things can go wrong in a quarter, even if I struggle to build a bear case here.
P.S. A quick and dirty way to value the company: $300M in Ion customer balances (as guided for next year) @ ~3% translates to $0.30+ in EPS. Apply a 10x multiple and you get $3.00+ per share. In other words, Ion alone gets you there. The PayFac flywheel, ACH tailwinds, school voucher programs, Title IV disbursements and the Harris partnership all come for free.
A few quotes from yday’s $USIO LD Micro presentation that dissect the full thesis:
1. ACH tailwinds and the growth flywheel
“Q3 for our ACH division set all-time records for us in volume. That is something really to say because we do a huge amount of volume in ACH. For us to grow that much, it is growing off a big number. Last quarter, third quarter, was the best ever, which beat the previous best, which was Q2 of this year. Q2 beat the previous best, which was Q1. I guess you’re kind of getting the story. The last six quarters have all record volumes for ACH. All-time records. Really excited about seeing that trend continue, but not only continue, continue in a big way for the third quarter.”
In fact, each business line is growing fast, even exponentially, w/ the exception of card issuing that has some meaningful programs launching soon.
2. Operating leverage
“We are really excited about the operating leverage that we are seeing... As we are making those new sales and our existing customer base is growing, we are not having to add incremental expenses, hire new people. We have the technology. You can see that those results are showing… Our tech stack is built. We just continue to evolve it. We do not really need to add SG&A to continue to add all this volume that we are doing. We might add some customer service positions because we have more accounts to support. That is not a huge SG&A hit.”
3. Catalyst #1: School voucher programs
“We currently, through a partner, process 37 state school voucher programs. In the past 12 months, that equates to $1.3 billion in payments. The great thing about these programs is they are recurring. Of those 37 states, five are active card programs… There is one additional state that is over a billion dollars that is in implementation, so really excited about this. Like I said, it is recurring payments. Just to give you an idea of the scale of a billion-dollar state, last year, Usio processed around $8 billion payments total. Therefore, the volume of these deals is significant.”
4. Catalyst #2: Usio Ion
“At any given time, we have between 80 and 100 million dollars of funds in our ecosystem. We believe that with Ion, there is access to another 300 million dollars in deposits. Why that is meaningful to us is when those funds are in our ecosystem, we are earning interest on that… It is a game changer for Usio as we increase our float, and that revenue goes straight to the bottom line.”
At the fed funds rate, that equates to $11-12M in 100% margin inflows. The CEO was even more optimistic later in the presentation:
“You know, we have today, every day, $80 million to $100 million that we’re earning interest off, that’s not our money. All of a sudden, that goes to $500 million. That is a new payment stream for us, income stream. It is 100% margin, so that will increase our margins quite a bit.”
5. Catalyst #3: Harris Computer
“Just a couple weeks ago, we announced a very exciting partnership with Harris Computer. Harris Computer is a massive organization under Constellation Software, which is a $60 billion company out of Canada. Harris Computer provides operating platforms for utilities and government entities. We partnered with Harris to be their preferred payments provider… This really is exciting for us. As you know, a single utility in San Antonio, for example, processes over a billion dollars in payments a year. When we are talking about the scale, it kind of blows what Usio in its current state out of the water. We are really excited about this.”
6. Catalyst #4: Guidance raise
“Looking forward, our guidance for the remainder of the year, which we raised after releasing Q2, is 14% to 16% revenue growth. We started the year with a 10% to 12% revenue growth. As you can see, the first half was at 17%. We remain conservative in our guidance and will continue to evaluate that as the remainder of the year progresses.”
The only chance to raise guidance is on Nov 10. Save the date.
Florian Buschek retweeted
$CLMT announced revised agreement w/ Warburg....
My reading of the tea leaves...
Cleans up capital structure for an outright sale of MRL as Calumet ownership of MRL goes from 87% to 100% (92% above $750M floor equity value).
A buyer can take control without negotiating with Warburg over its 13% stake. Warburg’s remaining claims are a fixed preferred balance, which gets paid off, and warrants that only matter above $750M floor.
Under the old terms, a "qualified IPO" was the event that turned Warburg’s 13% stake into common. With that stake now gone and structured as a call option above $750M floor, an IPO no longer hands Warburg 13%.
At 11.5%, Warburg’s preferred grows by about $45M a year, eating into the common equity Calumet owns. This gives Calumet a strong incentive to reach a liquidity event.
Florian Buschek retweeted
$CLMT highly credible and respected source told me that today, this afternoon actually, Motiva, the US base oil price leader, raised its price on its group II 600N base oil by 12% from $7.70/gal to $8.62. Pure margin. Unprecedented demand inelasticity.
The market is blind to the base oil bonanza extravaganza that’s NOT priced into $CLMT stock.
Friday.
Florian Buschek retweeted
This very interesting paper argues that global imbalances cannot be understood simply as the outcome of independent national saving and investment decisions. The structure of the international monetary and financial system helps shape those decisions, determines how capital flows across borders, and influences which countries bear the costs of adjustment.
Global imbalances are back, and the conventional diagnosis may be wrong.
Conventional analysis by the International Monetary Fund, G7 + OECD traces the imbalances to domestic saving–investment gaps, pointing to "excess saving in China and the EU, and too little saving in the United States."
In a new working paper, GDP Center Non-Resident Senior Fellow @YanLian31677392 + Center Director @KevinPGallagher argue that the root cause of the imbalances is in fact the financial imbalances generated by the international monetary and financial system (IMFS) itself. Dollar dominance and the lack of a credible global lender of last resort push countries to self-insure.
For this month's T20 Summit in New York, the authors contribute to a policy brief ahead of the December G20 Leaders' Summit. They present two priorities for G20 discussions on imbalances:
📍 Strengthening the global financial safety net (GFSN)
📍 Accelerating multilateral development bank (MDB) reform
The goal is to make these systems "not just bigger, but better."
📄 Read the working paper: gdpcenter.org/3UYqFCV
📄 Read the T20 policy brief: gdpcenter.org/47VEKUA
#G20 #IMF #OECD #T20 #GFSN #GlobalImbalances
Florian Buschek retweeted
$DAIO appointed Douglas Adams, formerly of Source Electronics and Avnet, as SVP Global Services, Support and Quality. The company says he joins CEO Bill Wentworth and Monty Reagan to lead its Programming-as-a-Service expansion as A&J Programming is integrated.
Florian Buschek retweeted
In 2010, @JohnHuber72 had a plan to raise money and buy 100 foreclosed homes.
He and a partner had spent the GFC buying houses from banks at 50 cents on the dollar. They peaked at 19 units. Shortly after, Blackstone and the big single-family rental funds moved into the same trade.
He passed. He didn’t want to spend the next decade managing houses.
He spent three years winding down the real estate and launched Saber Capital in 2013, modeled on Buffett’s 1950s partnership.
@iancassel and I sat down with John for our latest @MicroCapClub podcast.
In this episode, John explains why he moved away from his "never sell great businesses" rule. He uses Copart to show how a stock at 40 to 50 times earnings can fall 50% on a small hiccup. He also covers how he splits his portfolio between long-term compounders and a basket of Ben Graham-style bargains, how Pitney Bowes moved from one bucket to the other, and how he sizes positions so no single mistake can do serious damage. The conversation opens with his essay on the Tampa Bay Rays and what happens when everyone optimizes for the same metric.
Chapters
00:00 Intro
02:38 What the Tampa Bay Rays teach investors
09:58 Home runs vs base hits
11:29 When to sell a great business
15:41 Lessons from a self-taught investor dad
17:28 Why journalism makes better investors
19:11 Buying houses at 50 cents on the dollar
22:12 Why he walked away from real estate
24:16 Compounders vs bargains
27:51 When a turnaround becomes a compounder
32:04 Why he keeps an investment journal
34:14 Margins vs return on capital
38:39 Should you look for value overseas?
41:19 Inside his Ben Graham basket
42:31 How he sizes his biggest positions
45:38 Concentrated, but never fragile
48:01 Greenblatt, Schloss and many ways to win
51:04 How to stay in the game for decades
53:24 Why there’s no high-risk version of Saber
56:07 Do the work on your desk
In this conversation, @DavidBarbato_ and @iancassel sit down with @JohnHuber72
- John explains why he moved away from never selling great businesses.
-He covers how he splits his portfolio between long-term compounders and Ben Graham-style bargains
microcapclub.com/when-to-sel…









































